

AP3 Rec'd PCT/PTO 22 JUN 2021

SERIAL NO.

PTO/SB/08a

INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	620-442	Unknown Natl. Phase of PCT/GB2004/005421
<hr/>		
APPLICANT		
BORMAN ET AL.		
<hr/>		
(Use several sheets if necessary)	FILING DATE	TC/A.U.
	June 22, 2006	Unknown

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	International Search Report for PCT/GB04/05421 dated 2 May 2005.
	Szczepan Jozefowski et al., <i>Exogenous but not endogenous prostanoids regulate cytokine secretion from murine bone marrow dendritic cells: EP2, DP, and IP but not EP1, EP3, and FP prostanoid receptors are involved</i> , International Immunopharmacology, vol. 3, 1 June 2003, pp. 865-878, XP002325093.
	Nials et al, <i>AH13205, A Selective Prostanoid EP2-Receptor Agonist</i> , Cardiovascular Drug Reviews, vol. 11, no. 2, 1993, pp. 165-179, XP009004866.
	Vancheri et al., <i>The lung as a privileged site for the beneficial actions of PGE2</i> , Trends in Immunology, vol. 25, no. 1, January 2004, pp. 40-46, XP004481206.
	Kanda et al., <i>Prostaglandin E2 suppresses CCL27 production through EP2 and EP3 receptors in human keratinocytes</i> , Journal of Allergy and Clinical Immunology, vol. 114, no. 6, December 2004, pp. 1403-1409, XP004666387.
	Hillock et al., <i>Inhibitory Prostanoid EP Receptors in Human Non-Pregnant Myometrium</i> , European Journal of Pharmacology, vol. 378, no. 1, 28 July 1999, pp. 99-108, XP001124311.

***Examiner**

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.